Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE SODIUM versus TRUSOPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE SODIUM versus TRUSOPT.
ACETAZOLAMIDE SODIUM vs TRUSOPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
Carbonic anhydrase inhibitor; decreases aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes of the eye.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
One drop of 2% solution in affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Terminal elimination half-life of dorzolamide in whole blood is approximately 4 months due to tight binding to carbonic anhydrase in red blood cells; however, the drug's clinical effect on intraocular pressure has a half-life of about 24 hours.
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Renal excretion as unchanged drug: approximately 70% of a topically applied dose is excreted renally; the remainder is eliminated via biliary/fecal routes (30%). Following oral administration, renal excretion accounts for about 65-70%.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor